Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction

@article{Ewald2008MetaanalysisOB,
  title={Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction},
  author={Ben D. Ewald and D Ewald and Ammarin Thakkinstian and John Attia},
  journal={Internal Medicine Journal},
  year={2008},
  volume={38}
}
Background:  We set out to review the validity of tests for B type natriuretic peptide (BNP) and N‐terminal pro BNP (NTproBNP) in the diagnosis of clinical heart failure (HF) in primary care and hospital settings and to examine the effect of age. We also examined the accuracy of the test in population screening for left ventricular systolic dysfunction. 
View on Wiley
ncbi.nlm.nih.gov
117 Citations
Highly Influential Citations
2
Background Citations
18
Methods Citations
4
Results Citations
2

117 Citations

Citation Type

Citation Type

Left ventricular ejection fraction in addition to N-terminal pro-B-type natriuretic peptide for risk stratification in the ambulant elderly: get the picture...or not?
  • A. Richards
  • Medicine
  • Journal of the American College of Cardiology
  • 2011
TLDR
A report from the CHS (Cardiovascular Health Study) on an assessment of N-terminal prophylaxis in the elderly is reported. Expand
Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure
TLDR
The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment. Expand
N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.
TLDR
In CHF patients with severely impaired systolic function, NT-pro-BNP levels reflect LA and LV dysfunction, and should prompt studies to investigate the relationship between changes of LA function and NT- pro-BNp levels and their clinical value as prognostic and therapeutic targets in CHF. Expand
Hemoglobin Concentration Influences N‐Terminal Pro B‐Type Natriuretic Peptide Levels in Hospitalized Older Adults with and without Heart Failure
TLDR
To investigate the relationship between hemoglobin and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) concentration in hospitalized older adults with or without a diagnosis of heart failure, a large number of subjects were treated for heart failure. Expand
Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease
TLDR
While optimal diagnostic cutpoints for both markers varied depended on age and degree of renal dysfunction, and the clinical application; NT-proBNP had a much more widely variable optimal cutpoint than did BNP, sufficient evidence for clinical utility of both tests exists for other applications of prognosis, screening, and monitoring of heart failure. Expand
The role of b-type natriuretic peptide in heart failure management.
TLDR
There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Expand
Natriuretic peptide testing in primary care patients
TLDR
Plasma concentration of B-type-related natriuretic peptides is a marker of either hemodynamic or neurohormonal stress on the heart and has been validated within the diagnostic and prognostic domain in patients with suspected or ascertained heart failure, mostly in the in-hospital setting. Expand
Natriuretic peptide measurement in heart failure
This paper is an up-to-date account of research and current clinical practice guideline recommendations. Chris Higgins summarizes the recommendations of 2 new guidance documents on the use of… Expand
Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure.
TLDR
In this chapter, authors have studied the clinical impact of B-type natriuretic peptide assay in the follow-up of patients with heart failure, and, in particular, the possible role of the measurement of its circulating levels in guiding the treatment. Expand
Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients
TLDR
Nt-BNP and BNP are useful to discriminate between patients with regard to cardiac remodeling and might be considered a screening tool in order select patients eligible for further examination with UCG examination. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Use of NT‐proBNP in routine testing and comparison to BNP
TLDR
The aim of this study was to evaluate the new marker NT‐proBNP within a large, heterogeneous population of patients with suspected cardiovascular disease at risk of cardiovascular dysfunction and to compare it with the established diagnostic parameter BNP. Expand
Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure
TLDR
BNP and NT-proBNP may be equally useful as an aid in the diagnosis of CHF in short of breath patients presenting to the emergency department when compared by logistic regression models. Expand
Comparison of Brain Natriuretic Peptide and Probrain Natriuretic Peptide in the Diagnosis of Cardiogenic Pulmonary Edema in Patients Aged 65 and Older
TLDR
The aim of this study was to compare the usefulness of B‐type natriuretic peptide (BNP) and amino‐terminal fragment BNP (proBNP), to diagnose CPE in patients aged 65 and older. Expand
Diagnostic value of a rapid test for B‐type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender
B‐type natriuretic peptide (BNP) measurements are useful for diagnosing congestive heart failure (CHF) in patients presenting to the Emergency Department with acute dyspnoe. Whether the diagnostic… Expand
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.
TLDR
BNP can reliably screen diabetic patients for the presence or absence of left ventricular dysfunction, and in those patients who had a CIE, BNP levels showed a high positive predictive value for the detection of left Ventricular dysfunction. Expand
Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.
TLDR
It is demonstrated that N-BNP measurement significantly improves the diagnostic accuracy of HF by GPs over and above customary clinical review. Expand
Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.
TLDR
B-type natriuretic peptide blood concentration measurement appears to be a sensitive and specific test to diagnose CHF in urgent-care settings. Expand
Utility of N-terminal pro-brain natriuretic peptide for the diagnosis of heart failure.
TLDR
The results suggest that N-terminal pro-brain natriuretic peptide can be reliably used for the diagnosis of heart failure in an outpatient setting, and this will improve the ability of clinicians to differentiate patients with shortness of breath due to heart failure from those with other causes of shortnesses of breath. Expand
Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
TLDR
The performance of BNP and NT-ANP for detection of elevated LV mass and LVSD was suboptimal, suggesting limited usefulness of natriuretic peptides as mass screening tools. Expand
Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.
TLDR
Rapid measurement of BNP or NT-proBNP is useful in establishing or excluding the diagnosis of congestive heart failure in patients with acute dyspnea and appears as accurate as BNP according to area under ROC curve. Expand
...
1
2
3
4
5
...